Meet Our Advisors & Collaborators

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health for US Oncology Research. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Distinguished Professor Department Medical Oncology and Therapeutic Research at the City of Hope.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA-approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for the treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award and a named lectureship in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.  He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after  Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2400 clinical trial physicians.

Michele Reni, MD, is a Specialist in Medical Oncology at the Department of Medical Oncology at the San Raffaele Research Hospital in Milan. He is Director of the Strategic Program of Clinical Coordination of Pancreatic Center, and a Member of the Multidisciplinary team involved in the management of pancreatic adenocarcinoma.

Dr. Reni is an expert consultant for the European Medicines Agency (EMA); faculty member of the European Society of Medical Oncology (ESMO) for brain tumors; teacher at “Vita e Salute University”- School of Medicine and Surgery; peer reviewer for several international scientific journals and scientific societies; coordinator of the AIOM (Italian Association of Medical Oncology) guidelines for the management of pancreatic cancer; coauthor of the AIOM guidelines for the management of central nervous system tumors; steering committee member, chairman, co-chairman, or sub-investigator in more than 20 Phase II and III clinical trials.

Dr. Reni is also the author or co-author of more than 230 scientific articles published in peer-reviewed journals, and he has a national scientific qualification to university teaching as first-level professor.

Prof. Dr. Braumann is Chief of General, Visceral and Vascular Surgery at the E.v.K. Hospital Gelsenkirchen at the University of Duisburg-Essen Germany. He is also the Head of Molecular and Clinical Research of the Ruhr-University Bochum, Germany. He studied at Martin Luther University and the Free University of Berlin. He conducted research at the University of Cape Town, graduating in 1998 from Humboldt University, Berlin. In addition to his clinical work, Professor Braumann received support for interests outside of surgery, including molecular biology with a specialization in oncologic biology and molecular mechanistic regulation in adipositas. In 2005 Professor Braumann received the European Technology Award from the European Association of Endoscopic Surgery for the first description of the mechanism of an anti-coagulant substance. 

Professor Braumann’s clinical expertise is in the areas of general, visceral minimally invasive, endocrinic, and tumor surgery. He has led numerous clinical trials and was a member of the ethics committee appointed by the senate of Berlin. Professor Braumann is a member of the German Society of Surgery, The German Society for Visceral Surgery and the European Association for Endoscopic Surgery. 

Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988 and completed a residency in Obstetrics and Gynecology at the University of California, Los Angeles, in 1992. In 1995, after three fellowships in Medical Genetics and Gynecologic Oncology, Dr. Monk was appointed director of gynecologic oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was associate professor with tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, and director of research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed director and professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network. He was also appointed the US Oncology medical director of gynecologic oncology research. Dr. Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the American Society for Colposcopy and Cervical Pathology (ASCCP), as well as being an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO) and other professional organizations. He has authored more than 400 peer-reviewed articles along with more than 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life. He has led numerous clinical trials that have led to FDA approval of novel agents or changed the standard of care.

Dr. Robert Coleman is the Chief Medical Officer at the Vaniam Group.  He was previously at US Oncology Research as its Chief Scientific Officer,  and  previously served as the Ann Rife Cox Chair in Gynecology and a professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center (MDACC), as well as executive director for MDACC’s Cancer Network Research Program. He is also a member of the board of directors for the Gynecologic Oncology Group (GOG) Foundation and co-director of GOG Partners.  Dr. Coleman won the Rosalind Franklin Excellence in Ovarian Cancer Research Award (2018) and is a past president of the Society for Gynecologic Oncology (2015). He is the current president of the International Gynecologic Cancer Society. In 2020 Dr. Coleman was included in the top 15 Giants in Cancer Care program recognition program which celebrates the achievements of leading researchers and educators whose discoveries have helped propel the field forward and established the building blocks for future advances. 

Thomas Herzog, MD, is the Deputy Director of the University of Cincinnati Cancer Center and is the Paul and Caroline Flory Endowed Professor of Obstetrics and Gynecology at the UC College of Medicine.

Dr. Herzog graduated from the University of Cincinnati College of Medicine in 1986. He completed his residency at Good Samaritan Hospital in Cincinnati followed by a  fellowship in gynecologic oncology at the Washington University School of Medicine, St. Louis, before becoming a faculty member at Washington University and then director of the gynecologic oncology fellowship program. In 2004, he became the director of the division of gynecologic oncology at Columbia University and started the fellowship at Columbia and Cornell Universities.

Dr, Herzog is a National Institutes of Health- and American Cancer Society-funded researcher with over 320 published manuscripts. He’s also been in a leadership position of a number of national professional societies including the Society of Gynecologic Oncology, American College of Surgeons, for which he was also on the elected board of governors, the American Board of Obstetrics and Gynecology, and the American Society for Colposcopy and Cervical Pathology, among others. Dr. Herzog served as editor-in-chief of the journal Gynecologic Oncology Research to Practice and The Women’s Oncology Review in addition to being on the editorial boards for a number of other peer-reviewed journals. He currently serves as the Associate Director of the GOG-Partners clinical trials organization.